Gilead, Merck launch Phase II trial evaluating oral regimen for HIV-1 treatment November 1, 2021 Auto Bot Clinical Development 0 The trial will evaluate a weekly regimen of islatravir and lnecapavir in HIV patients who are virologically suppressed while on antiretroviral therapies.